Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$15.99
$0.01(0.11%)
At close: 4:00 PM EST
$15.99
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.22M
Market Cap
$1.32B
Enterprise Value$818.43M
Total Cash (Recent Filing)$204.02M
Total Debt (Recent Filing)$21.30M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Mar 05, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding82,787,220
10 Day Avg. Volume1,151,310
30 Day Avg. Volume1,220,889
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue19.33
Enterprise Value/Gross Profit20.55
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$31.50Price Target Upside97.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.03
Revenue Forecast (FY)$31.76M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBoth Phase 3 trials of DURAVYU in wet AMD, LUGANO and LUCIA, have completed enrollment, which indicates progress in their clinical development.
Market PositioningDuravyu could be the first long-acting TKI for wet AMD to file an NDA and potentially the first to market, offering a potential competitive advantage.
Regulatory Approval PathwayEYPT has pursued a well-established regulatory path for wet AMD approval, indicating a strategic approach.
Bears Say
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $3.91 and its highest was $19.11 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $1.32B.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is in 80 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 05, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.769 by -$0.081.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.74.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 82,787,220 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.769. Following the earnings report the stock price went down -11.057%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (97.00% Upside)
$31.50 (97.00% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 445.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.38%
12-Months-Change
Fundamentals
Return on Equity
-98.23%
Trailing 12-Months
Asset Growth
-16.36%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals (EYPT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for diseases of the eye. The company specializes in its proprietary drug delivery technologies, which are designed to enhance the effectiveness of ophthalmic treatments. EyePoint's core product offerings include products for the treatment of retinal diseases and other serious eye conditions, leveraging its platform to provide sustained delivery of medication, thus improving patient outcomes.
EYPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint demonstrated strong clinical progress with successful trial enrollments and maintained a robust financial position to support future operations. However, the company faced challenges with decreased revenue and increased operating expenses leading to a higher net loss. Despite financial setbacks, the strategic advancements in clinical programs and regulatory alignments position EyePoint for continued growth and potential market leadership.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$31.50
▲(97.00% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.75% Insiders
15.00% Mutual Funds
36.75% Other Institutional Investors
38.65% Public Companies and
Individual Investors